SGMT (Sagimet Biosciences Inc. Series A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SGMT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-17 | George Kemble | Director | MIXED | — | — |
| 2026-08-12 | George Kemble | Director | MIXED | — | — |
| 2026-07-22 | Elizabeth Rozek | Chief Legal & Admin. Officer | Sell | — | — |
| 2026-07-22 | David Happel | President & CEO | Sell | — | — |
| 2026-07-22 | George Kemble | Director | Sell | — | — |
| 2026-06-15 | BETH C SEIDENBERG | Director | A | — | — |
| 2026-06-15 | Paul W. Hoelscher | Director | A | — | — |
| 2026-06-15 | Anne M. Phillips | Director | A | — | — |
| 2026-06-15 | George Kemble | Director | A | — | — |
| 2026-06-15 | Jennifer Jarrett | Director | A | — | — |
| 2026-06-15 | ELIZABETH A GRAMMER | Director | A | — | — |
| 2026-06-01 | Andreas Grauer | Chief Medical Officer | A | — | — |
| 2026-06-01 | David Happel | President & CEO | A | — | — |
| 2026-06-01 | Elizabeth Rozek | Chief Legal & Admin. Officer | A | — | — |
| 2026-06-01 | Thierry Chauche | Chief Financial Officer | A | — | — |
| 2026-05-14 | Andreas Grauer | Chief Medical Officer | A | — | — |
| 2026-02-20 | Thierry Chauche | Chief Financial Officer | A | — | — |
| 2026-02-20 | Elizabeth Rozek | Chief Legal & Admin. Officer | A | — | — |
| 2026-02-20 | David Happel | President & CEO | A | — | — |
| 2026-02-20 | Eduardo Bruno Martins | Chief Medical Officer | A | — | — |
| 2026-02-12 | Thierry Chauche | Chief Financial Officer | Sell | — | — |
| 2026-02-12 | Elizabeth Rozek | Chief Legal & Admin. Officer | Sell | — | — |
| 2026-02-12 | Eduardo Bruno Martins | Chief Medical Officer | Sell | — | — |
| 2026-02-12 | David Happel | President & CEO | Sell | — | — |
| 2025-11-21 | George Kemble | Executive Chairman | Sell | — | — |
| 2025-11-06 | Elizabeth Rozek | Chief Legal & Admin. Officer | A | — | — |
| 2025-07-23 | Eduardo Bruno Martins | Chief Medical Officer | Sell | — | — |
| 2025-07-23 | David Happel | President & CEO | Sell | — | — |
| 2025-07-23 | Elizabeth Rozek | General Counsel and CCO | Sell | — | — |
| 2025-06-10 | Paul W. Hoelscher | Director | A | — | — |
| 2025-06-10 | ELIZABETH A GRAMMER | Director | A | — | — |
| 2025-06-10 | Anne M. Phillips | Director | A | — | — |
| 2025-06-10 | Timothy P Walbert | Director | A | — | — |
| 2025-06-10 | George Kemble | Director | A | — | — |
| 2025-06-10 | BETH C SEIDENBERG | Director | A | — | — |
| 2025-06-10 | Jennifer Jarrett | Director | A | — | — |
| 2025-02-07 | Elizabeth Rozek | General Counsel and CCO | A | — | — |
| 2025-02-07 | David Happel | President & CEO | A | — | — |
| 2025-02-07 | Thierry Chauche | Chief Financial Officer | A | — | — |
| 2025-02-07 | Eduardo Bruno Martins | Chief Medical Officer | A | — | — |
| 2024-08-05 | Jennifer Jarrett | Director | A | — | — |
| 2024-08-05 | Anne M. Phillips | Director | A | — | — |
| 2024-07-25 | George Kemble | Executive Chairman | Sell | — | — |
| 2024-07-23 | Elizabeth Rozek | General Counsel and CCO | Sell | — | — |
| 2024-07-23 | George Kemble | Executive Chairman | Sell | — | — |
| 2024-07-23 | Eduardo Bruno Martins | Chief Medical Officer | Sell | — | — |
| 2024-06-07 | BETH C SEIDENBERG | Director | A | — | — |
| 2024-06-07 | ELIZABETH A GRAMMER | Director | A | — | — |
| 2024-06-07 | Timothy P Walbert | Director | A | — | — |
| 2024-06-07 | Merdad Parsey | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,261,225 | — |
| — | 10%+ Owner | 3,013,414 | — |
| — | 10%+ Owner | 3,000,275 | — |
| — | 10%+ Owner | 3,000,275 | — |
| — | 10%+ Owner | 3,000,275 | — |
| — | 10%+ Owner | 1,899,475 | — |
| — | Director | 1,654,701 | — |
| — | President & CEO | 741,570 | — |
| — | Executive Chairman | 413,148 | — |
| — | Chief Legal & Admin. Officer | 224,414 | — |
| — | Chief Medical Officer | 147,296 | — |
| — | Director | 84,768 | — |
| — | Chief Financial Officer | 59,688 | — |
| — | Director | 12,794 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SGMT quote page; the site-wide leaderboard is on the insider transactions hub.